Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1349235 10.3389/fphar.2023.1349235 Pharmacology Retraction Retraction: Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin Frontiers Editorial Office 10.3389/fphar.2023.1349235 Frontiers Editorial Office *

Approved by: Olivier Feron, Université catholique de Louvain, Belgium

 *Correspondence: Frontiers Editorial Office, research.integrity@frontiersin.org 07 12 2023 2023 14 1349235 04 12 2023 04 12 2023 Copyright © 2023 Frontiers Editorial Office. 2023 Frontiers Editorial Office

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Retraction of the Original Research Article Berberine maintains the neutrophil N1 phenotype to reverse cancer cell resistance to doxorubicin by Zhang S, Zhou L, Zhang M, Wang Y, Wang M, Du J, Gu W, Kui F, Li J, Geng S and Du G (2020). Front. Pharmacol. 10:1658. doi: 10.3389/fphar.2019.01658 section-at-acceptance Pharmacology of Anti-Cancer Drugs

The journal retracts the 29 January 2020 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors agree to this retraction.